对前列腺癌活组织检查中的 27 种 HPV 基因型进行高灵敏度的深层面板测序，结果发现检出率非常低，表明 HPV 并不是这种恶性肿瘤的主要病因。

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2024-11-14 DOI:10.1186/s13027-024-00619-x

Karoline Andersen, Paul Vinu Salachan, Michael Borre, Benedicte Ulhøi, Magnus Stougaard, Karina Dalsgaard Sørensen, Torben Steiniche

{"title":"对前列腺癌活组织检查中的 27 种 HPV 基因型进行高灵敏度的深层面板测序，结果发现检出率非常低，表明 HPV 并不是这种恶性肿瘤的主要病因。","authors":"Karoline Andersen, Paul Vinu Salachan, Michael Borre, Benedicte Ulhøi, Magnus Stougaard, Karina Dalsgaard Sørensen, Torben Steiniche","doi":"10.1186/s13027-024-00619-x","DOIUrl":null,"url":null,"abstract":"Background: Human papillomavirus (HPV) has been proposed to contribute to the carcinogenesis of prostate cancer. However, previous studies have yielded conflicting results. This study aims to add useful information to the ongoing discussion concerning the association between HPV infection and prostate cancer.Methods: We used two high-throughput next-generation sequencing (NGS) approaches to detect HPV RNA in malignant and adjacent normal (AN) prostate tissue (cohorts 1 and 2) and HPV DNA from carcinogenic and probably/possibly carcinogenic-classified HPV types (cohort 3) in malignant prostate, AN prostate, and benign prostatic hyperplasia (BPH) tissues.Results: In total, 0% (cohort 1: 0/83, cohort 2: 0/16) of the malignant prostate tissue samples and 0% (cohort 1: 0/23, cohort 2: 0/8) of the AN prostate tissue samples were positive for HPV RNA. A total of 8.3% (1/12) of the BPH samples, 0% (0/28) of the AN samples, and 0.8% (1/132) of the malignant prostate samples were positive for HPV16 DNA. However, the normalized read count of the HPV16-positive malignant sample was close to the cut-off. In addition, no other carcinogenic-classified HPV types were detected in any of the BPH, AN, or malignant prostate tissue samples.Conclusion: Our study does not support HPV infection as a major contributor to the etiology of prostate cancer.","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"19 1","pages":"57"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566718/pdf/","citationCount":"0","resultStr":"{\"title\":\"Highly sensitive deep panel sequencing of 27 HPV genotypes in prostate cancer biopsies results in very low detection rates and indicates that HPV is not a major etiological driver of this malignancy.\",\"authors\":\"Karoline Andersen, Paul Vinu Salachan, Michael Borre, Benedicte Ulhøi, Magnus Stougaard, Karina Dalsgaard Sørensen, Torben Steiniche\",\"doi\":\"10.1186/s13027-024-00619-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Human papillomavirus (HPV) has been proposed to contribute to the carcinogenesis of prostate cancer. However, previous studies have yielded conflicting results. This study aims to add useful information to the ongoing discussion concerning the association between HPV infection and prostate cancer.Methods: We used two high-throughput next-generation sequencing (NGS) approaches to detect HPV RNA in malignant and adjacent normal (AN) prostate tissue (cohorts 1 and 2) and HPV DNA from carcinogenic and probably/possibly carcinogenic-classified HPV types (cohort 3) in malignant prostate, AN prostate, and benign prostatic hyperplasia (BPH) tissues.Results: In total, 0% (cohort 1: 0/83, cohort 2: 0/16) of the malignant prostate tissue samples and 0% (cohort 1: 0/23, cohort 2: 0/8) of the AN prostate tissue samples were positive for HPV RNA. A total of 8.3% (1/12) of the BPH samples, 0% (0/28) of the AN samples, and 0.8% (1/132) of the malignant prostate samples were positive for HPV16 DNA. However, the normalized read count of the HPV16-positive malignant sample was close to the cut-off. In addition, no other carcinogenic-classified HPV types were detected in any of the BPH, AN, or malignant prostate tissue samples.Conclusion: Our study does not support HPV infection as a major contributor to the etiology of prostate cancer.\",\"PeriodicalId\":13568,\"journal\":{\"name\":\"Infectious Agents and Cancer\",\"volume\":\"19 1\",\"pages\":\"57\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566718/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Agents and Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13027-024-00619-x\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-024-00619-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：人类乳头瘤病毒（HPV）被认为是前列腺癌的致癌因素之一。然而，以往的研究结果却相互矛盾。本研究旨在为正在进行的有关人乳头瘤病毒感染与前列腺癌之间关系的讨论提供有用信息：我们使用两种高通量新一代测序（NGS）方法检测了恶性前列腺组织和邻近正常（AN）前列腺组织（队列 1 和 2）中的 HPV RNA，以及恶性前列腺、AN 前列腺和良性前列腺增生（BPH）组织中致癌和可能/疑似致癌分类 HPV 类型（队列 3）的 HPV DNA：共有 0% 的恶性前列腺组织样本（群组 1：0/83，群组 2：0/16）和 0% 的良性前列腺增生组织样本（群组 1：0/23，群组 2：0/8）HPV RNA 呈阳性。共有8.3%（1/12）的良性前列腺增生样本、0%（0/28）的恶性前列腺样本和0.8%（1/132）的恶性前列腺样本的HPV16 DNA呈阳性。不过，HPV16 阳性恶性样本的归一化读数接近临界值。此外，在任何良性前列腺增生症、恶性前列腺增生症或恶性前列腺组织样本中均未检测到其他致癌分类的HPV类型：我们的研究并不支持将 HPV 感染作为前列腺癌的主要病因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Highly sensitive deep panel sequencing of 27 HPV genotypes in prostate cancer biopsies results in very low detection rates and indicates that HPV is not a major etiological driver of this malignancy.

Background: Human papillomavirus (HPV) has been proposed to contribute to the carcinogenesis of prostate cancer. However, previous studies have yielded conflicting results. This study aims to add useful information to the ongoing discussion concerning the association between HPV infection and prostate cancer.

Methods: We used two high-throughput next-generation sequencing (NGS) approaches to detect HPV RNA in malignant and adjacent normal (AN) prostate tissue (cohorts 1 and 2) and HPV DNA from carcinogenic and probably/possibly carcinogenic-classified HPV types (cohort 3) in malignant prostate, AN prostate, and benign prostatic hyperplasia (BPH) tissues.

Results: In total, 0% (cohort 1: 0/83, cohort 2: 0/16) of the malignant prostate tissue samples and 0% (cohort 1: 0/23, cohort 2: 0/8) of the AN prostate tissue samples were positive for HPV RNA. A total of 8.3% (1/12) of the BPH samples, 0% (0/28) of the AN samples, and 0.8% (1/132) of the malignant prostate samples were positive for HPV16 DNA. However, the normalized read count of the HPV16-positive malignant sample was close to the cut-off. In addition, no other carcinogenic-classified HPV types were detected in any of the BPH, AN, or malignant prostate tissue samples.

Conclusion: Our study does not support HPV infection as a major contributor to the etiology of prostate cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.